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Background: In approximately the year 2000, the results of a number of important studies of
non-small-cell lung cancer (NSCLC) were published.
Methods: Between July 1992 and December 2003, 223 patients with NSCLC aged 70 years
received chemotherapy alone as their initial treatment at the National Cancer Center Hospital
East. These patients were divided into 2 groups: those that began treatment between 1992 and
1999 (group A) and between 2000 and 2003 (group B). The details of chemotherapy regimens
and outcomes were compared.
Results: In group A, 83% of patients received platinum-based chemotherapy, two-thirds of
these regimens comprised platinum plus second-generation combination chemotherapy. In
contrast, although 55% of patients received platinum-based chemotherapy in group B, 41%
of patients received non-platinum-based chemotherapy. Among patients in group B,
performance status was significantly associated with the selection of platinum-based or non-
platinum-based chemotherapy; age was marginally associated with this selection. Median
survival time (MST), 1-year survival rate, and 2-year survival rate were 6.7 months, 14%, and
7%, respectively, in group A, and 8.1 months, 35%, and 20% in group B (pZ 0.0109). Multivar-
iate analysis revealed that clinical stage and administration of salvage chemotherapy were
independent prognostic factors.
Conclusions: In and after the year 2000, chemotherapy regimens changed greatly and survival
of elderly patients significantly improved in our institute, and this improvement appears to be
attributable mostly to the effect of salvage chemotherapy. These results suggest that even
elderly patients should be offered salvage chemotherapy regardless of age, if possible.
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Chemotherapy for NSCLC in the elderly 435Introduction Materials and methodsLung cancer is the leading cause of cancer-related death in
many industrialized countries. Non-small cell lung cancer
(NSCLC) accounts for approximately 80%e85% of all lung
cancers, and the majority of patients have metastatic
disease at the time of diagnosis.1 Previous data indicate
that more than 50% of advanced NSCLC are diagnosed in
patients aged 65 years and about 30%e40% are diagnosed
in patients 70 years of age.2 NSCLC can therefore be
regarded as a disease of the elderly, and the proportion of
older adults among NSCLC patients is expected to
progressively increase due to the aging of the populations
of most developed countries.
Platinum-based combination chemotherapy improves
survival and quality-of-life (QOL) in patients with
advanced NSCLC, and is now widely accepted as the
standard in chemotherapy.3,4 However, platinum-based
chemotherapy is often contraindicated in elderly patients
because of patient deficits in functional status and organ
function. In addition, elderly patients have approxi-
mately twice as many comorbidities as the general pop-
ulation.5,6 Past studies on the effect of age on treatment
choices for advanced NSCLC have revealed that elderly
patients were less likely to receive active treatments.7e9
Until recently, clinical trials for NSCLC have not specifi-
cally examined the importance of chronological age or
the desirability of an upper age limit for treatment.
Indeed, it has been reported that elderly patients are
under-represented in those trials. In fact, according to
a survey conducted by the Southwest Oncology Group,
only 39% of patients enrolled in lung cancer trials
between 1993 and 1996 were older than age 65, even
though such patients represent 66% of the overall cancer
patient population.10
The lack of clinical data on elderly NSCLC patients
encouraged physicians to carry out elderly-specific clin-
ical trials. In the 1990s, third-generation cytotoxic
agents, such as vinorelbine (VNR), gemcitabine, doce-
taxel (DOC), paclitaxel, and irinotecan, were developed,
and single-agent chemotherapy regimens using these
agents were investigated in many phase II trials. In 1999,
the results of the first elderly-specific phase III trial
comparing VNR to best supportive care were published.11
In that study, a significant survival benefit was seen in
patients receiving VNR. Furthermore, VNR was well
tolerated and QOL scores were better in patients treated
with VNR. Then, in 2000, 2 phase III trials revealed
a survival benefit for DOC when used as second-line
chemotherapy agent, which was the first evidence for the
effectiveness of second-line chemotherapy for
NSCLC.12,13 In addition, in 2002, as compared to
other countries, approval for gefitinib, epidermal growth
factor tyrosine kinase inhibitor (EGFR-TKI), was granted
early in Japan.
These results should have a significant impact on clinical
practice relating to advanced NSCLC in the elderly. In this
study, we reviewed data on chemotherapy regimens used in
the treatment of elderly NSCLC patients at our institute,
and compared regimens and patient outcomes before and
after year 2000.Patients
Between July 1992 and December 2003, 223 NSCLC patients
aged 70 years received chemotherapy alone as their
initial treatment at the National Cancer Center Hospital
East. These patients were divided into 2 groups: those that
began treatment between 1992 and 1999 (group A) and
those that began treatment between 2000 and 2003 (group
B). Chemotherapy regimens and outcomes were then
compared between groups. Group B patients were then
subdivided into 2 groupsdthe platinum-based chemo-
therapy group and the non-platinum-based chemotherapy
groupdand the clinical factors responsible for treatment
choice were then analyzed. In addition, Group B patients
were subdivided into another two groups; EGFR-TKI treated
group or not-treated group. All patient data were obtained
from our database.
Tumor evaluation and statistical analysis
Survival time was measured from the start of chemotherapy
to either the time of death from any cause or the date
patients were last known to be alive. The survival curve was
estimated using the Kaplan-Meier method, and compared
by using the log-rank test. Comparisons between individual
clinical factors were performed using the c2 test. Multi-
variate analysis was conducted according to the Cox
proportional hazards model. P< 0.05 was considered to
denote statistical significance. All statistical analyses were
performed using StatView, Version 5.0 (Abacus Concepts,
Berkley, CA).
Results
Patient characteristics
Patient characteristics are listed in Table 1. There were 74
patients in group A and 149 in group B. Median age was
almost identical, but the proportion of patients aged 75
years was significantly higher in group B (pZ 0.0182). Other
clinical factors, including sex, performance status (PS),
tumor histology, disease stage, and smoking history, were
not significantly different between the groups.
First-line chemotherapy
Details of first-line chemotherapy are shown in Table 2. In
group A, 83% of patients received platinum-based chemo-
therapy; two-thirds of these were platinum-based plus
second-generation combination chemotherapy regimens. In
group B by contrast, although 55% of patients received
platinum-based chemotherapy, 41% received non-platinum-
based chemotherapy and 4% received epidermal growth
factor receptor tyrosine kinase inhibitor (EGFR-TKI). EGFR-
TKI as first-line treatment was all clinical trial settings. In
group B, second-generation agents were no longer used,
and the most frequently administered third-generation
single-agent chemotherapy was VNR.
Table 1 Patient characteristics (nZ 223).
Group A
(’92e’99)
Group B
(’00e’03)
P
No. of patients 74 149
Age
Median 73 74
<75 55 (75%) 86 (58%) 0.0182*
75 19 (25%) 63 (42%)
Sex
Male 62 (84%) 115 (78%) 0.29
Female 12 (16%) 34 (22%)
ECOG PS
0e1 69 (93%) 136 (91%) 0.8
2 5 (7%) 13 (9%)
Histology
Ad 52 (70%) 84 (56%) 0.06
Non-Ad 22 (30%) 65 (44%)
Stage
IIIb 25 (34%) 55 (37%) 0.66
IV 49 (66%) 94 (63%)
Smoking history
Current/former 62 (84%) 119 (80%) 0.59
Never 12 (16%) 30 (20%)
ECOG, Eastern Clinical Oncology Group; PS, performance
status.
Table 2 First-line chemotherapy.
Group A
(’92e’99)
Group B
(’00e’03)
Platinum-based
Platinumþ 2nd-generation 41 (56%) 0 (0%)
CDDPþ VDSþMMC 26 0
CDDPþ VDS 14 0
254Sþ VDS 1 0
Platinumþ 3rd-generation 20 (27%) 83 (55%)
CDDPþ VNR 3 44
CDDPþ DOC 15 15
CBDCAþ PTX 0 12
CDDPþ VNRþGEM 0 5
CDDPþGEM 0 4
CDDPþ CPT-11 2 3
Non-platinum-based
2nd-generation 3 (4%) 0 (0%)
ETP 3 0
3rd-generation (mono) 7 (10%) 29 (20%)
VNR 2 23
DOC 0 5
GEM 0 1
PTX 3 0
CPT-11 2 0
3rd-generation (doublet) 2 (3%) 31 (21%)
GEMþ VNR 2 31
EGFR-TKI 0 (0%) 6 (4%)
Gefitinib 0 6
CDDP, cisplatin; VDS, vindesine; MMC, mitomycin C; 254S,
nedaplatin; VNR, vinorelbine; DOC, docetaxel; CBDCA, carbo-
platin; PTX, paclitaxel; GEM, gemcitabine; CPT-11, irinotecan;
ETP, etoposide.
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based and non-platinum-based chemotherapy
In group B, 143 patients (96%) received platinum-based or
non-platinum-based chemotherapy; only 6 patients (4%)
received EGFR-TKI. In order to determine the clinical
factors that affected the selection of platinum-based and
non-platinum-based chemotherapy, relevant clinical
factors were individually compared between these 2
patient subgroups. As shown in Table 3, only PS significantly
differed between groups: patients with a PS of 0 or 1 ten-
ded to receive platinum-based chemotherapy; those with
a PS of 2 tended to receive non-platinum-based chemo-
therapy (pZ 0.004). Other clinical factors did not signifi-
cantly differ between the groups; however, the proportion
of patients aged 75 years was marginally higher in the
non-platinum-based chemotherapy group (pZ 0.0596).
EGFR-TKI treatment
In group B, 34 patients received EGFR-TKI treatment during
entire treatment period, while no patients in group A. In
group B, the proportion of patients who received EGFR-TKI
was significantly higher in female, adenocarcinoma, and
never-smoked patients (Table 4).
Second-line chemotherapy and beyond
The characteristics of patients who underwent multiple-
line chemotherapy are shown in Table 5. In group A,
second-line chemotherapy was administered to only 4
patients (5%) and no patients underwent third-line
chemotherapy. In group B by contrast, second-line andthird-line chemotherapy was administered to 62 (42%) and
22 (15%) patients, respectively. DOC was the agent most
frequently used in second-line chemotherapy; EGFR-TKI
was the most common agent for third-line chemotherapy.
Survival
Median survival time (MST) was 6.7 months in group A and
8.1 months in group B (pZ 0.0109). The 1-year survival rate
and 2-year survival rate were 14% and 7%, respectively, in
group A, and 35% and 20% in group B. Survival curves are
shown in Fig. 1. The relationships between clinical variables
and survival are shown in Table 6. Univariate analysis
revealed that female, stage IIIB, never-smoker, EGFR-TKI
treatment, and the administration of salvage chemo-
therapy were associated with better survival. However,
multivariate analysis demonstrated that only clinical stage
and the administration of salvage chemotherapy were
independent prognostic factors.
Discussion
In approximately the year 2000, the results of large phase III
trials of treatments for advanced NSCLC were published.
The findings of these studies were of great importance in
understanding how to treat elderly patients with NSCLC. In
Table 3 Patient characteristics of Group B (platinum vs
non-platinum).
Platinum-
based
Non-
platinum-based
P
No. of patients 83 60
Age
Median 73 74
<75 55 (66%) 28 (47%) 0.0596
75 30 (34%) 32 (53%)
Sex
Male 66 (80%) 47 (78%) >0.9999
Female 17 (20%) 13 (22%)
Performance status
0e1 81 (98%) 50 (83%) 0.0040*
2 2 (2%) 10 (17%)
Histology
Ad 51 (61%) 29 (48%) 0.1283
Non-Ad 32 (39%) 31 (52%)
Stage
IIIb 33 (40%) 21 (35%) 0.6032
IV 50 (60%) 39 (65%)
Smoking history
Current/former 66 (80%) 49 (82%) 0.8326
Never 17 (20%) 11 (18%)
Ad, adenocarcinoma.
Table 5 The number of patients receiving multiple
chemotherapies (nZ 223).
Group A (’92e’99) Group B (’00e’03)
2nd-line yes 4 (5%) 62a (42%)
no 70 (95%) 87 (58%)
3rd-line yes 0 (0%) 22b (15%)
no 74 (100%) 127 (85%)
4th-line yes 0 (0%) 9 (6%)
no 74 (100%) 140 (94%)
a docetaxel 27; EGFR-TKI 12; platinum-based 12; others 11.
b EGFR-TKI 14; docetaxel 1; others 7.
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the impact of those trials by reviewing the records of 223
patients aged 70 years who began chemotherapy between
1992 and 2003 at our institute and comparing treatment
details between those who began chemotherapy between
1992 and 1999 (group A) and those who began treatment
between 2000 and 2003 (group B).Table 4 Patient characteristics of Group B (EGFR-TKI
treated vs not EGFR-TKI treated).
EGFR-TKI (þ) EGFR-TKI () P
No. of patients 34 115
Age
Median 73 74
<75 25 (74%) 61 (53%) 0.0473*
75 9 (26%) 54 (47%)
Sex
Male 19 (56%) 96 (83%) 0.0019
Female 15 (44%) 19 (17%)
Performance status
0e1 30 (88%) 106 (92%) 0.4944
2 4 (12%) 9 (8%)
Histology
Ad 27 (79%) 57 (50%) 0.0028*
Non-Ad 7 (21%) 58 (50%)
Stage
IIIb 11 (32%) 44 (38%) 0.6862
IV 23 (68%) 71 (62%)
Smoking history
Current/former 21 (62%) 98 (85%) 0.0061*
Never 13 (38%) 17 (15%)
Ad, adenocarcinoma.As we anticipated, the proportion of patients who
received non-platinum-based chemotherapy, with either 1
or 2 agents, was higher in group B; however, more than 50%
of patients in group B still received platinum-based
chemotherapy. We further investigated group B to deter-
mine what clinical factors were associated with the selec-
tion of platinum-based or non-platinum-based chemotherapy.
The results were unsurprising: patients with a PS of 2 or
aged 75 tended to receive non-platinum-based chemo-
therapy. Several sub-group analyses from phase III trials
indicated that, when PS was not impaired, platinum-based
chemotherapy was equally safe and effective in patients
aged over and under 70 years.14e17 The first elderly-specific
trial comparing platinum-based and non-platinum-based
chemotherapy regimens also indicated that patients aged
70e74 years might derive more benefit from platinum-
based chemotherapy than from non-platinum-based
chemotherapy.18 However, it is unclear whether platinum-
based chemotherapy is safe and effective for patients aged
75 years.
In the present study, the proportion of patients who
received salvage chemotherapy was also higher in group B.
While only 5% of patients received second-line chemo-
therapy in group A, 42% received second-line chemotherapy
in group B. In 15% of patients in group B, third-line
chemotherapy was also administered.0
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Figure 1 Kaplan-Meier curve of overall survival in all patients
(nZ 232). Median survival time, 1-year survival rate, and 2-year
survival rate were 6.7 months, 14%, and 7%, respectively, in
group A, and 8.1 months, 35%, and 20% in group B.
Table 6 Multivariate analysis for survival.
Variables Category MST (months) Univariate
p
Multivariate
Risk ratio 95%CI p
Age <70 7.6 0.6 1.0930 0.815e1.465 0.5529
70 7.0
Sex Female 9.7 0.0012* 1.4060 0.798e2.476 0.2382
Male 7.0
PS 0-1 7.5 0.15 1.3030 0.783e2.169 0.3084
2 4.0
Histology Ad 7.5 0.06 0.8300 0.623e1.106 0.2034
non-Ad 6.7
Stage IIIB 9.3 0.0094* 0.6120 0.524e0.949 0.0213*
IV 6.8
Smoking history () 9.2 0.0062* 0.8510 0.634e2.044 0.6630
(þ) 7.0
Platinum-doublet () 7.3 0.86 1.1260 0.829e1.529 0.4466
(þ) 7.1
3rd-generation agent () 6.7 0.27 0.8640 0.596e1.252 0.4392
(þ) 7.3
EGFR-TKI () 6.7 <0.0001* 0.7900 0.453e1.379 0.4077
(þ) 15.0
Salvage chemotherapy () 5.8 <0.0001* 0.5100 0.335e0.776 0.0017*
(þ) 12.6
EGFR-TKI, epidermal growth factor receptor-tyrosine kinase inhibitor; Ad, adenocarcinoma.
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as compared with group A, and multivariate analysis
revealed that clinical stage and the administration of
salvage chemotherapy were independent prognostic
factors. Between group A and B, the difference of clinical
stage was not significant. Therefore, these results seem to
be the effect of salvage chemotherapy and suggest that
even elderly patients should be offered salvage chemo-
therapy regardless of age, if possible. To date, several
agents, such as docetaxel, gefitinib, erlotinib, and peme-
trexed, have been approved as salvage chemotherapy
worldwide, including Japan.19 Physicians should not miss
a chance to offer these effective agents to elderly patients.
In conclusion, in our institute, chemotherapy regimens
changed considerably after the year 2000. In addition,
survival time significantly improved after 2000, and this
improvement appears to be attributable mostly to the
effect of salvage chemotherapy.
Conflict of interest statement
None of the authors have a conflict of interest to declare in
relation to this work.
References
1. Gridelli C. Does chemotherapy have a role as palliative therapy
for unfit or elderly patients with non-small-cell lung cancer?
Lung Cancer 2002;38(Suppl. 2):S45e50.2. Gridelli C, Aapro M, Ardizzoni A, et al. Treatment of advanced
non-small-cell lung cancer in the elderly: results of an inter-
national expert panel. J Clin Oncol 2005;23(13):3125e37.
3. Schiller JH, Harrington D, Belani CP, et al. Comparison of four
chemotherapy regimens for advanced non-small-cell lung
cancer. N Engl J Med 2002;346(2):92e8.
4. Ohe Y, Ohashi Y, Kubota K, et al. Randomized phase III study of
cisplatin plus irinotecan versus carboplatin plus paclitaxel,
cisplatin plus gemcitabine, and cisplatin plus vinorelbine for
advanced non-small-cell lung cancer: four-arm cooperative
study in Japan. Ann Oncol 2007;18(2):317e23.
5. Gridelli C, Shepherd FA. Chemotherapy for elderly patients
with non-small cell lung cancer: a review of the evidence.
Chest 2005;128(2):947e57.
6. Gridelli C, Langer C, Maione P, Rossi A, Schild SE. Lung cancer
in the elderly. J Clin Oncol 2007;25(14):1898e907.
7. Smith TJ, Penberthy L, Desch CE, et al. Differences in initial
treatment patterns and outcomes of lung cancer in the elderly.
Lung Cancer 1995;13(3):235e52.
8. Brown JS, Eraut D, Trask C, Davison AG. Age and the treatment
of lung cancer. Thorax 1996;51(6):564e8.
9. EarleCC,Venditti LN,NeumannPJ,etal.Whogets chemotherapy
for metastatic lung cancer? Chest 2000;117(5):1239e46.
10. Hutchins LF, Unger JM, Crowley JJ, Coltman Jr CA, Albain KS.
Underrepresentation of patients 65 years of age or older in
cancer-treatment trials. N Engl J Med 1999;341(27):2061e7.
11. Effects of vinorelbine on quality of life and survival of elderly
patients with advanced non-small-cell lung cancer. The elderly
lung cancer vinorelbine Italian study group. J Natl Cancer Inst
1999;91(1):66e72.
12. Shepherd FA, Dancey J, RamlauR, et al. Prospective randomized
trial of docetaxel versus best supportive care in patients with
Chemotherapy for NSCLC in the elderly 439non-small-cell lung cancer previously treated with platinum-
based chemotherapy. J Clin Oncol 2000;18(10):2095e103.
13. Fossella FV, DeVore R, Kerr RN, et al. Randomized phase III trial
of docetaxel versus vinorelbine or ifosfamide in patients with
advanced non-small-cell lung cancer previously treated with
platinum-containing chemotherapy regimens. The TAX 320
non-small cell lung cancer study group. J Clin Oncol 2000;
18(12):2354e62.
14. Kelly K, Giarritta S, Akerley W, et al. Should older patient (pts)
receive combination chemotherapy for advanced stage non-
small cell lung cancer (NSCLC)? Ananalysis of Southwest oncology
trials 9509 and 9308. Proc Am Soc Clin Oncol 2001;20:329a.
15. Langer CJ, Manola J, Bernardo P, et al. Cisplatin-based therapy
for elderly patients with advanced non-small-cell lung cancer:
implications of Eastern cooperative oncology group 5592,
a randomized trial. J Natl Cancer Inst 2002;94(3):173e81.16. Langer CJ, Vangel J, Schiller DP, et al. Age-specific subanalysis
of ECOG 1594: fit elderly patients (70e80 yrs) with NSCLC do as
well as younger patients (<70). Proc Am Soc Clin Oncol 2003;
22:639a.
17. Goto K, Nishiwaki Y, Saijo N, et al. The four-arm cooperative
study (FACS) for advanced non-small cell lung cancer (NSCLC):
a subgroup analysis in elderly patients. Proc Am Soc Clin Oncol
2006;24:7115a.
18. Tsukada H, Yokoyama A, Nishiwaki Y, et al. Randomized
controlled trial comparing docetaxel (D)-cisplatin (P) combi-
nation with D alone in elderly patients (pts) with advanced
non-small cell lung cancer (NSCLC): JCOG0207. Proc Am Soc
Clin Oncol 2007;25:7629.
19. Stinchcombe TE, Socinski MA. Considerations for second-line
therapy of non-small cell lung cancer. Oncologist 2008;
13(Suppl. 1):28e36.
